药物耐药的表皮 fugax: 响应于对abotulinumtoxinA的反应
Francisco José Alberola-Amores1, Jorge Moral-Rubio1
1Headache Unit, Department of Neurology, Hospital General Universitario de Elche, Elche, Spain.
Headache
|June 20, 2023
概括
发性头痛 (Epicrania fugax) 是一种罕见的头痛,涉及到短暂而强烈的疼痛. 毒素A对两名没有对其他治疗有反应的患者提供了持续的缓解.
科学领域:
- 神经学 神经学
- 头痛 医学 医学 医学
背景情况:
- 发性头痛 (Epicrania fugax,EF) 是一种主要的头痛,其特征是短暂的发性疼痛发作.
- 攻击通常持续1-10秒,并在一个半骨内遵循线性或曲的路径.
- 目前的治疗方法包括抗发作药物和更大的头神经阻塞,有效性各不相同.
研究的目的:
- 报告在Epicrania fugax患者中,对标准治疗不耐药的ONabotulinumtoxinA的疗效.
主要方法:
- 根据国际头痛疾病分类,第三版标准,诊断出Epicrania fugax的两名患者的病例报告.
- 患者呈现出明显的触发因素和自主眼部征兆.
- 在干预之前,记录了多种常规预防疗法的失败.
主要成果:
- 两位患者都经历了持续的积极反应,对onabotulinumtoxinA治疗.
- 在这些耐火病例中,治疗有效地控制了发性EF型疼痛.
结论:
- 毒素A可能是Epicrania fugax的可行的治疗选择,特别是在对已知的治疗方法耐药的患者中.
- 需要进一步的研究来证实对Epicrania fugax. onabotulinumtoxinA的疗效和最佳使用.
相关概念视频
Allergic Drug Reactions
898
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
898
Cross-reactivity
31.3K
Overview
31.3K
Allergic Reactions
27.9K
Overview
27.9K
Antiepileptic Drugs: Potassium Channel Activators
218
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
218
Depolarizing Blockers: Pharmocokinetics
353
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
463
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
463


